Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
ASCO-GU 2026 – gauging Welireg’s double win
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
Genmab taps ProfoundBio again
After several discontinuations, a new ADC enters the clinic.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ASCO-GU 2026 – Protara gets that sinking feeling
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
ASCO-GU 2026 – casdatifan starts to look competitive
Median PFS appears to back earlier response rate promise.
